Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 10:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,040 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Diabetic Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Lifestyle Intervention in Preparation for Pregnancy (LIPP)

NCT03146156
View directory record Official record
Conditions
Obesity, Lifestyle-related Condition, Macrosomia, Fetal
Interventions
Lifestyle Intervention
Behavioral
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2025
U.S. locations
4
States / cities
Baton Rouge, Louisiana • Boston, Massachusetts • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 27, 2025 · Synced Sep 7, 2026, 10:34 AM EDT
Completed No phase listed Observational

International Consortium Investigating Early Vitrectomy in Diabetic Macular Edema Patients

NCT02639507
View directory record Official record
Conditions
Diabetes With Diabetic Retinopathy With Macular Edema
Interventions
Vitrectomy
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
2
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 25, 2020 · Synced Sep 7, 2026, 10:34 AM EDT
Completed No phase listed Observational

Comparing Visual Acuity Measurements (How Well You Can See) Using a Standard ETDRS Chart & a Handheld ETDRS Chart

NCT01622816
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Not listed
Lead sponsor
Julia Haller
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 9, 2016 · Synced Sep 7, 2026, 10:34 AM EDT
Completed Phase 3 Interventional Results available

Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy

NCT01057693
View directory record Official record
Conditions
Diabetic Neuropathy, Painful
Interventions
pregabalin (Lyrica), Placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
633 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
150
States / cities
Birmingham, Alabama • Northport, Alabama • Gilbert, Arizona + 120 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Sep 7, 2026, 10:34 AM EDT
Terminated Not applicable Interventional

Efficacy of Near Infrared Phototherapy in Type 2 Diabetic Neuropathy

NCT02798393
View directory record Official record
Conditions
Neuropathy
Interventions
Infrared Phototherapy, Sham
Other
Lead sponsor
Healthlight, LLC
Industry
Eligibility
25 Years to 90 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Topeka, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Sep 7, 2026, 10:34 AM EDT
Completed Phase 4 Interventional

GrafixPRIME® for the Treatment of Chronic Diabetic Foot Ulcers

NCT02675855
View directory record Official record
Conditions
Foot Ulcer, Diabetic
Interventions
GrafixPRIME®, Dressing Application, Off-loading (walking boot)
Other · Procedure · Device
Lead sponsor
Osiris Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
3
States / cities
Arizona City, Arizona • California City, California • New Mexico, New Mexico
Source: ClinicalTrials.gov public record
Updated Jul 16, 2017 · Synced Sep 7, 2026, 10:34 AM EDT
Completed Not applicable Interventional

Effect of Changing Diet on Fasting and Post Fat Load Lipoproteins

NCT00593424
View directory record Official record
Conditions
Hypertriglyceridemia, Diabetes Mellitus
Interventions
Low Fat/High Carbohydrate, High Monounsaturated Fat/Low Carbohydrate
Other
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Sep 1, 2011 · Synced Sep 7, 2026, 10:34 AM EDT
Not listed No phase listed Observational

Patient Empowerment Study

NCT04537676
View directory record Official record
Conditions
Diabetic Foot, Quality of Life, Mental Health Wellness 1, Ulcer Foot, Diabetes Complications
Interventions
No intervention, this is an observational study
Other
Lead sponsor
Podimetrics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Somerville, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Sep 7, 2026, 10:34 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy of Aliskiren in the Treatment of Diabetic Macular Edema

NCT00768040
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Aliskiren, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
10
States / cities
Phoenix, Arizona • Los Angeles, California • Fort Myers, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2012 · Synced Sep 7, 2026, 10:34 AM EDT
Completed Not applicable Interventional

Effect of Discontinuation of Sugar Sweetened Beverages

NCT00585897
View directory record Official record
Conditions
Type 2 Diabetes, Obesity
Interventions
discontinuation of sugar sweetened beverages
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 13, 2015 · Synced Sep 7, 2026, 10:34 AM EDT
Completed Phase 4 Interventional

Grafix® DFU: Open-Label Extension Option to Evaluate Safety & Efficacy of Grafix® for Chronic Diabetic Foot Ulcers

NCT01596920
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
Tissue, Control
Other
Lead sponsor
Osiris Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
15
States / cities
Montgomery, Alabama • Glendale, Arizona • Encinitas, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2014 · Synced Sep 7, 2026, 10:34 AM EDT
Completed Phase 4 Interventional Results available

Study of Oasis Ultra in Diabetic Foot Ulcers

NCT01835379
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
Oasis, Standard
Device · Other
Lead sponsor
Healthpoint
Industry
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
16
States / cities
Little Rock, Arkansas • Carlsbad, California • Fair Oaks, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2015 · Synced Sep 7, 2026, 10:34 AM EDT
Completed No phase listed Observational

Diabetic Retinopathy and Visual Function Study

NCT00001346
View directory record Official record
Conditions
Diabetic Retinopathy, Macular Degeneration, Vision, Subnormal
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 7, 2026, 10:34 AM EDT
Completed Phase 4 Interventional Results available

A Randomized Double-Blind Study Testing the Effects of Pregabalin on Diabetic Neuropathy

NCT00573261
View directory record Official record
Conditions
Diabetic Neuropathy
Interventions
Pregabalin, Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 20, 2014 · Synced Sep 7, 2026, 10:34 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of Tapentadol ER Compared With Placebo in Patients With Chronic, Painful Diabetic Peripheral Neuropathy

NCT01041859
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy
Interventions
Tapentadol extended release (ER), Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
60
States / cities
Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2013 · Synced Sep 7, 2026, 10:34 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes

NCT01011868
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
BI 10773 placebo, BI 10773 low dose, BI 10773 high dose
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
494 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
56
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 50 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2014 · Synced Sep 7, 2026, 10:34 AM EDT
Completed Not applicable Interventional

Matrion™ Decellularized Placental Membrane in Subjects With Diabetic Foot Ulcers

NCT05087758
View directory record Official record
Conditions
Diabetic Foot, Lower Extremity Wound
Interventions
Matrion, Conventional Care Wound Management
Other
Lead sponsor
LifeNet Health
Industry
Eligibility
21 Years to 80 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
8
States / cities
Tucson, Arizona • Carmichael, California • Fresno, California + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Sep 7, 2026, 10:34 AM EDT
Recruiting Not applicable Interventional

The GRoceries Aimed at Increasing Nutrition Study

NCT07167004
View directory record Official record
Conditions
Type 2 Diabetes, Type II Diabetes Mellitus, Type II Diabetes, Pre-diabetes, Pre-diabetic, Pre-diabetic State, Type 2 Diabetes Mellitus (T2DM), Type 2 Diabetes Mellitus, Type 2 Diabetes (T2DM)
Interventions
Marketing Nudges Only, Marketing Nudges + Dynamically Adapted Financial Incentives
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
45 Years to 70 Years
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 7, 2026, 10:34 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate an Updated Dexamethasone Intravitreal (Into the Eye) Applicator in Adult Participants With Macular Edema Due to Diseases of the Retina

NCT04976777
View directory record Official record
Conditions
Macular Edema
Interventions
Updated DEX PS DDS Applicator, Approved DEX PS DDS Applicator, Dexamethasone
Device · Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
Glendale, California • North Dartmouth, Massachusetts • Independence, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Sep 7, 2026, 10:34 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Resveratrol in Type2 Diabetes and Obesity

NCT01158417
View directory record Official record
Conditions
Type 2 Diabetes, Obesity, Insulin Resistance
Interventions
Placebo, Resveratrol 40 mg oral three times a day, Resveratrol 500 mg oral once daily.
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
20 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Williamsville, New York
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Sep 7, 2026, 10:34 AM EDT
Completed Phase 2 Interventional

Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease

NCT00811889
View directory record Official record
Conditions
Chronic Kidney Disease, Type 2 Diabetes, Diabetic Nephropathy
Interventions
Placebo, Bardoxolone Methyl (RTA 402)
Other · Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
42
States / cities
Birmingham, Alabama • Montgomery, Alabama • Chula Vista, California + 36 more
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Sep 7, 2026, 10:34 AM EDT
Completed Phase 3 Interventional Results available

30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks

NCT01183013
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Pioglitazone 15 mg, Pioglitazone 45 mg, Pioglitazone 30 mg, Linagliptin 5mg / Pioglitazone 45 mg FDC, Linagliptin 5mg / Pioglitazone 30 mg FDC, Linagliptin 5mg, Linagliptin 5mg / Pioglitazone 15 mg FDC
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
936 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
74
States / cities
Birmingham, Alabama • Montgomery, Alabama • Muscle Shoals, Alabama + 60 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2014 · Synced Sep 7, 2026, 10:34 AM EDT
Terminated Phase 3 Interventional

Open-Label Study in Diabetic Foot Ulcers (DFU), to Evaluate Safety of 0.03% DSC127 Topical Gel in Chronic Use

NCT01840085
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
0.03% DSC127 topical gel
Drug
Lead sponsor
Integra LifeSciences Corporation
Industry
Eligibility
18 Years and older
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
21
States / cities
Mobile, Alabama • Chino, California • Fresno, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Sep 7, 2026, 10:34 AM EDT
Completed Phase 2 Interventional

A Clinical Study of the Safety and Efficacy of MEBO® Wound Ointment in Subjects With Diabetic Foot Ulcers (Pilot)

NCT01154374
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
MEBO Wound Ointment, Standard of Care (sterile saline moistened gauze)
Drug · Procedure
Lead sponsor
Skingenix, Inc.
Industry
Eligibility
18 Years to 79 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
New Haven, Connecticut • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Sep 7, 2026, 10:34 AM EDT